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Biomarkers that evaluate the response to erythropoietic-
stimulating agents largely measure inflammation and iron
availability. While these are important factors in modifying an
individual’s response to these agents, they do not address all
aspects of a poor response. To clarify this, we isolated
peptides in the serum of good and poor responders to
erythropoietin in order to identify biomarkers of stimulating
agent response. Ninety-one candidate biomarker targets
were identified and characterized using mass spectrometry,
of which tandem mass spectroscopy provided partial
amino-acid sequence information of 17 different peptides for
16 peptide masses whose abundance significantly differed
between poor and good responders. The analysis concluded
that three peptides associated with a poor response were
derived from oncostatin M receptor b (OSMRb). The 13 serum
peptides associated with a good response were derived from
fibrinogen a and b, coagulation factor XIII, complement C3,
and cysteine/histidine rich 1(CYHR1). Poor response was
most strongly associated with the OSMRb fragment with the
largest molecular weight, while a good response was most
strongly associated with CYHR1. Immunoblots found the
abundance of intact OSMRb and CYHR1 significantly differed
between good and poor responders. Thus, two measurable
biomarkers of the response to erythropoietic-stimulating
agents are present in the serum of treated patients.
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The administration of an exogenous erythropoietic-stimulating
agent (ESA) is required in many patient populations in order
to maintain hemoglobin concentrations 410 g/dl. Central
to the current discussion of ESAs is the identification of
patients who respond normally to pharmacologic concentra-
tions of erythropoietin (EPO) (good response) and those
patients who do not (poor response). Patients who are poor
responders to EPO may be at risk for increased morbidity
and mortality,1 and the inability to reach a higher target
hemoglobin than previously recommended in combination
with an increased epotin-a dose is associated with an
increased risk of death, myocardial infarction, congestive
heart failure, or stroke.2
In general, the causes of nonresponse to an ESA are well
documented and appear to affect B10% of the population.3
The three most common reasons for nonresponse are
noncompliance, absolute or functional iron deficiency, and
inflammation,4 with intercurrent infection probably the most
common reason for temporary resistance. Other reasons for
non or poor response include inadequate dose, secondary
hyperparathyroidism, aluminum toxicity, hemolysis, malig-
nancies, thalassemia, sickle cell disease, AIDS, pregnancy,
vitamin deficiency,3,5 and rarely antibodies to EPO.6 A recent
review of the literature identifies cytokines7 (interleukin (IL)-
1, IL-6, interferon-g, tumor necrosis factor), hepcidin, EPO
receptor (EpoR), and subsequent intracellular signaling as
regulators of EPO responsiveness.8 Furthermore, there is an
interaction between IL-6 and hepcidin that is responsible for
hypoferremia that may limit ESA response.9,10 Soluble EpoR
concentrations are also associated with EPO resistance in
end-stage renal disease.11,12
We addressed the hypothesis that there are qualitative and
quantitative differences in serum proteins in a group of
idiopathic poor responders to EPO that are predictive
of poor EPO response. We undertook an examination of a
population of patients without obvious signs of inflamma-
tion or iron deficiency and other overt reasons for poor
response in an attempt to identify biomarkers of
EPO response. To address this hypothesis we performed a
top-down liquid chromatography-matrix-assisted laser
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desorption-ionization time-of-flight tandem mass spectro-
metry (LC-MALDI-TOF MS/MS) peptidomic analyses to
compare serum peptides from patients with either a good or
a poor response to EPO.
RESULTS
The demographics of the enrolled subjects are shown in
Table 1. There were significant differences in ESA dose and
average EPO response index, defined as the EPO dose divided
by the resulting hemoglobin 1 month later, between the two
study groups. The distribution of gender between groups was
different but did not reach statistical significance. The reasons
for exclusion in the study population are shown in Table 2.
One sample in the good responder group yielded insufficient
bound peptide solution to proceed with LC-MALDI.
Each subject’s serum was assayed for C-reactive protein,
serum hepcidin, IL-6, IL-7, IL-8, IL-10, and tumor necrosis
factor-a. These data are shown in Figures 1 and 2. The results
of the statistical analyses are shown in Table 3. The only
difference detected was an interaction between group and
gender in hepcidin, IL-6, and IL-8 where there appeared to be
increased serum levels of hepcidin, IL-6, and IL-8 in male
poor responders.
Analysis of MS data
In general, most peptides were of low abundance and
infrequently observed across all samples. A total of 939 freely
soluble serum peptide masses were observed inX28 (82% of
samples) serum samples. A total of 130 masses were observed
in all 34 samples. Using t-test, 40 peptides were observed to
be differentially abundant with significance at the Pp0.05
level and 3 peptides at the Pp0.001 level (Supplementary
Table S1 online). A total of 558 protein-bound serum peptide
masses were observed in X28 serum samples. A total of
90 masses were observed in all 34 samples. Using t-test,
51 peptides were observed to be differentially abundant
with significance at the Pp0.05 level and 9 peptides at
the Pp0.001 level (Supplementary Table S1 online). To
graphically illustrate these data, plots of significance (P-
value) versus serum abundance differences in good responder
to poor responder (serum abundance ratio) for freely soluble
(Figure 3a) and protein-bound serum peptides were
constructed (Figure 3b) and annotated to indicate assign-
ment of protein identities to respective data points.
Mann and Kelleher have suggested fold expression changes
of 1.3 to X2.0 to be meaningful for MS-based proteomics
Table 1 | Demographics of the subject population at the time
of sample collection
Good
responder
Poor
responder P-value
Gender (M/F) 10/5 7/13 0.06a
Hemoglobin (g/dl) 11.5±0.6 11.2±1.1 0.4
ESA dose (U/treatment) 1467±673 8392±5833 o0.001
Total iron dose (5 months) (mg) 953±1187 2035±1604 0.035
Average ERI 0.11±0.036 0.87±0.51 o0.001
Kt/V 1.53±0.25 1.58±0.27 0.5
Albumin (g/dl) 3.9±0.3 3.8±0.3 0.3
Ferritin 767±353 781±416 0.9
Tsat (%) 30.5±7.9 26.4±16.5 0.4
Abbreviations: ERI, erythropoietin response index; ESA, erythropoietic-stimulating
agent; F, female; Kt/V, adequacy of dialysis; M, male; Tsat, transferrin saturation.
aPearson’s w2.
Table 2 | Description of subjects who were reviewed for
inclusion in the study and a list of the reasons for subjects
who were excluded
Study population
Active in-center patients 187 Subjects
Deceased 13
Transferred or new modality 21
Incomplete data 5
Subjects evaluated for inclusion 148 Subjects
o3 Months EPO out of 5 months 23
Calculated ERI
35 Lowest ERI
(good responder)
35 Highest ERI
(poor responder)
Hepatitis C 9 6
Active lupus 1 1
Active infection 2 0
Malignancy 0 1
Valve disease 0 1
Refused consent 7 6
Final subjects 15 20
Abbreviations: EPO, erythropoietin; ERI, erythropoietin response index.
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Figure 1 |Plot of serum C-reactive protein (CRP) and hepcidin from subjects displayed according to group and gender. Mean values
are displayed where the vertical line and middle horizontal line intersect. The upper and lower horizontal lines represent the s.d.
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experiments.13 Our criteria for selecting peptides for tandem
MS analysis to gain amino-acid sequence information
(peptides with P-values p0.05) and differential abundance
(abundance changes of X133 or p75% in good and poor
responders) identified 38 freely soluble serum peptides (95%
of all observed free peptides with P-value o0.05) and 50
protein-bound serum peptides (98% of all observed bound
peptides with a P-value o0.05) and demonstrated fold-
abundance changes of X1.3. For purposes of emphasis,
peptides estimated to have t-test P-values p0.001 are
highlighted in Figure 3 within the inset boxes.
Identification of peptide amino-acid sequences using
MS/MS methods
Amino-acid sequences were tentatively assigned to a total of
16 peptides (Table 4) corresponding to six parent proteins.
These peptide fragments were derived from a fibronectin III
domain of oncostatin M receptor b chain (OSMRb)
(Figure 4a–c), fibrinogen a chain (FGA), fibrinogen/fibrino-
peptide B (FGB), a fragment of the signal peptide region
of the cysteine and histidine-rich protein 1 (CYHR1)
(Figure 5a), coagulation factor XIII chain A (F13A), and
complement C3 (CO3). One peptide (1534.689 m/z) was
assigned slightly different but overlapping amino-acid
sequences by the Mascot and the Paragon algorithms. Seven
peptide masses required post-translational modifications to
explain MS/MS fragmentation spectra. Four peptides were
N-terminally modified, including two FGA modifications
that were assigned a mass value only. One FGA modification
was assigned as a post-translationally hydroxylated phenyla-
lanine, given that the F27Y polymorphism has not been
reported. One FGB peptide was assigned with an N-terminal
pyro-glutamate residue resulting from an N-terminal gluta-
mine rearrangement. Two OSMR peptides were assigned
(Supplementary Methods) mass values consistent with
modifications including di-sodiation (þ 45.99 m/z) and
O-glucosamine modification.
Differential expression of intact OSMRb and CYHR1 in
patient serum
An OSMR-positive band was identified in denaturing
conditions migrating at 50 kDa (Figure 4e) and was
significantly (Po0.05) increased (75% above poor respon-
ders) in the serum of good responders. The analysis of these
samples using nonreducing and denaturing sodium dodecyl
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Figure 2 |Plot of serum interleukin (IL)-6, IL-7, IL-8, IL-10, and tumor necrosis factor-a (TNF-a) from subjects displayed according
to group and gender. Mean values are displayed where the vertical line and middle horizontal line intersect. The upper and lower
horizontal lines represent the s.d.
Table 3 | Results of the statistical analysis of the CRP,
hepcidin, and cytokine data
P-value
Group Gender Interaction
CRP 0.11 0.98 0.83
Hepcidin 0.068 0.11 0.043
IL-6 0.71 0.18 0.018
IL-7 0.37 0.26 0.59
IL-8 0.57 0.58 0.046
IL-10 0.11 0.19 0.16
TNF-a 0.51 0.97 0.76
Abbreviations: CRP, C-reactive protein; IL, interleukin; TNF-a, tumor necrosis factor-a.
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sulfate-polyacrylamide gel electrophoresis identified OSMR
bands migrating at 100–110 kDa (data not shown) with a like
expression trend. Similarly, CHYR1 was identified (Figure 5c)
and validated using immunogen peptide blocking experi-
ments (Figure 5d) migrating at B72 kDa and was signifi-
cantly (Figure 5b; Po0.05) increased in the serum of EPO
poor responders (30% above good responders).
Summary statistical analysis
Summary statistics for all identified peptides are shown in
Table 5. In the case of OSMRb and FGA, more than one
fragment of a parent protein was identified and a Bonferroni
adjusted P-value is shown and an analysis of the sum of
the fragment abundances was performed. In addition, the
receiver operating characteristic value associated with the
sensitivity and specificity of the peptide to predict either
good or poor response was calculated.
DISCUSSION
Our goal was to identify serum peptides associated with a
poor response to EPO. We studied patients who routinely
attended their dialysis session, received adequate EPO and
iron dosing, and did not appear to have risk factors for EPO
failure, such as chronic inflammation or infection. Using a
peptidomic approach to generate MS data and develop a list
of differentially abundant peptides and ranked on P-values,
we assigned amino-acid sequences to 16 peptides whose
serum abundance significantly differed between poor and
good responders for further analysis. Three of the serum
peptides associated with poor EPO response through
sequence alignment of the peptides to the parent protein
were found to be derived from the fibronectin III domain of
the OSMRb chain. The 13 serum peptides associated with
good EPO response were concluded to be derived from FGA,
FGB, FXIIIA, CO3, and CYHR1.
We performed an immunoblot analysis of the serum for
the presence of OSMRb (reducing and nonreducing condi-
tions) and CYHR1 (reducing conditions) in a subset of the
total population. The results of the OSMRb immunoblot
experiments suggest that receptor is present in the serum as a
dimer. The molecular weight of the receptor observed in
reducing conditions is consistent with molecular weights for
shed OSMR, leukemia inhibitory factor, and IL-6R ecto-
domains.14,15 We were able to demonstrate the presence of
both intact proteins in serum, with OSMR increased in the
serum of good responders and CYHR1 increased in the
serum of poor responders.
OSMR intact protein is high in the serum of good
responders, whereas peptide fragments are high in poor
responders. For CYHR1, intact protein is high in the serum
of poor responders, whereas peptide fragments are high in
the serum of good responders. We speculate that the
difference is because of altered catabolism of OSMR and
CYHR1 over the range of EPO response index or increased
receptor turnover in the case of OSMR. Animal data appear
to support this speculation for OSMR, where OSMR
knockout mice have low hematocrit and decreased red
blood cells.16
These findings were not confounded with other measured
markers of EPO response. We did not observe differences
between poor and good responders for C-reactive protein,
hepcidin, IL-6, IL-7, IL-8, IL-10, tumor necrosis factor-a,
transferrin saturation, ferritin, and albumin. There was a
significant interaction between responder type and gender for
hepcidin, IL-6, and IL-8. We feel that the gender interaction
is most likely related to several male poor responders who
showed signs of inflammation in their measured laboratory
values.
We have two novel peptidomic findings in this study.
Three fragments of OSMRb are strongly associated with poor
EPO response and one fragment of CYHR1 is strongly
associated with good EPO response. Oncostatin-M (OSM) is
proposed to be an important EpoR-phosphoY343-Stat5-
induced gene product that participates in erythroblast
survival.17 OSM is secreted from cytokine-activated T cells
and monocytes and is involved in inflammation.18,19 OSM
binds to two different OSM receptors in humans: the type 1
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Figure 3 |Graphic comparison of the change in peptide
abundance in good- to poor-responder serum samples with
the corresponding statistical significance P-value for each
peptide. The t-test and ratio data are plotted using log–log
graphing for each significant peptide from the freely soluble
serum peptide (a) and protein-bound serum peptide (b) fractions.
The shaded region denotes masses with a P-value o0.001. When
possible, the parent protein for each protein fragment is
annotated with the appropriate protein accession number. In
some cases, multiple peptides originated from the sample protein
and result in the multiple annotations of the same gene accession
number. CO3, complement C3; CYHR1, cysteine and histidine-rich
protein 1; FGA, fibrinogen a chain; FGB, fibrinogen/fibrinopeptide
B; F13A coagulation factor XIII chain A.
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Table 4 | Assignment of peptide sequence to differentially expressed serum peptides.
Paragon
Observed
mass (m/z) Parent protein name
Amino acid
Amino-acid sequencea
Post-translational
modification
Mascot
MOWSE
unused
scoreb
Freely soluble Increased serum abundance with good response
1194.521 Fibrinogen a chain D.SGEGDFLAEGGGV.R 46 14
1399.623 Fibrinogen a chain S.GEGDFLAEGGGVR.G (N-term +136.16) 116c
1463.656 Fibrinogen a chain A.DSGEGDFLAEGGGVR.G 14.0
1481.653 Fibrinogen a chain A.DSGEGDFLAEGGGVR.G Phe-4Tyr@7 132 14
1534.689 Fibrinogen a chain D.ADSGEGDFLAEGGGVR.G 14.0
1534.689 Fibrinogen a chain D.SGEGDFLAEGGGVR.G (N-term +183.98) 93c
2466.054 Fibrinogen a chain S.SSYSKQFTSSTSYNRGDSTFES.K 55 14
2553.101 Fibrinogen a chain K.SSSYSKQFTSSTSYNRGDSTFES.K 75 14
2768.252 Fibrinogen a chain K.SSSYSKQFTSSTSYNRGDSTFESKS.Y 115 14
2931.292 Fibrinogen a chain K.SSSYSKQFTSSTSYNRGDSTFESKSY.K 63 14
1552.673 Fibrinogen b chain S.QGVNDNEEGFFSAR.G Gln-4pyro-Glu@N-term 2.7
Serum protein
bound
Increased serum abundance with good response
1210.582 Coagulation factor XIII A chain M.SETSRTAFGGR.R Acetyl@N-term 2.0
1488.800 Cysteine and histidine-rich protein 1 L.SHLVLGVVSLHAAVS.T 1.3d
1504.82 Complement C3 G.SPMYSIITPNILR.L 46 2
Freely soluble Increased serum abundance with poor response
1273.633 Oncostatin-M-specific receptor subunit b E.NKEVEEERIAG.T 50 2.1
1549.774 Oncostatin-M-specific receptor subunit b E.NKEVEEERIAGTE.G (C-term + 45.99) 48c
1664.801 Oncostatin-M-specific receptor subunit b E.NKEVEEERIAGTE.G (T(12) +161.02) 49c
aAmino-acid sequence is presented using Paris Convention guidelines for presenting proteomics data. The proteolytic excision sites are offset with periods. Amino acids
within periods comprise the amino-acid sequence for the observed peptide.
bProtein Pilot Paragon confidence interval scoring for the protein and the peptides listed were 99% (unused score X2.0) with simultaneous adjustment for decoy data base
analysis and removal of false-positive identifications.
cMatrix Science Mascot MOWSE score following post hoc error-tolerant analysis.
dProtein Pilot Paragon confidence interval scoring was 95% (unused score=1.3) with simultaneous adjustment for decoy data base analysis and removal of false-positive identifications.
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Figure 4 |Distribution of serum oncostatin M receptor b (OSMRb) fragments and protein levels associated with erythropoietic-
stimulating agent (ESA) responsiveness. Peptide abundance data were extracted from aligned mass spectrometry (MS) data sets and
peptide spectral abundance was calculated from the MS ion cluster area.10 For purposes of illustration, peptides not observed in particular
samples were assigned non-zero background abundance values arbitrarily equal to 10. Vertical scatter plots (mean±s.e.m.) for the
differences in serum abundance for (a–c) three OSMRb fragments and for (d, e) densitometry measurements of circulating OSMRb illustrate
significant differences in abundance between good-response (GR) and poor-response (PR) groups.
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receptor is identical to leukemia inhibitory factor receptor
that consists of gp130, also found in the IL-6 receptor, and
the type 2 receptor that consists of gp130 and OSM-specific
receptor b subunit (OSMR);20,21 the OSMR fragments
identified in the serum of our patients are from the type 2
receptor. Animal studies indicate that OSMR has an
important role in erythropoiesis, and OSMR knockout mice
have decreased number of circulating red blood cells and a
decreased hematocrit compared with wild type.13 OSMR
knockout mice also have decreased numbers of erythroid
colony-forming units and erythrocyte-producing colonies in
the bone marrow. Work in human fibroblast or epithelial cells
show that OSM ligand binding to OSMR induces receptor
degradation and then increases the level of receptor
synthesis.22 In hepatocytes and hepatoma cells, OSM induces
hypoxia-inducible factor 1a gene transcription via a Janus
kinase/signal transducer.23 Considered in the context of the
literature that indicates that OSM helps regulate erythropoi-
esis, the fact that we observed increased abundance of
OSMR fragments in patients with poor EPO response might
be expected.
The finding of a fragment of CYHR1 in the serum of our
study subjects was unexpected. Analysis of the estimated
amino-acid sequence suggests the fragment is derived
from the signal peptide sequence of CYHR1. This
CYHR1 fragment is almost as good a predictor of good
response (receiver operating characteristic¼ 0.91) as OSMR
is a predictor of poor response (receiver operating
characteristic¼ 0.98). The current state of knowledge on
CYHR1 is limited regarding its predicted protein structure,
protein–protein interactions, subcellular localization, and
chromosome mapping. CYHR1 is proposed to contain four
functional transmembrane helices and was first identified
using a yeast two-hybrid system to search for cytoplasmic
proteins that associate with galectin-3.24 Further work was
performed using recombinant hamster galectin-3 and murine
CYHR1 and demonstrated that CYHR1 binds to the
carbohydrate-recognition domain of galectin-3.25
FGA, FGB, FXIIIA, and CO3 had increased abundances in
good responders and are likely related to low levels of
inflammation that are present in hemodialysis patients.26
The prediction of EPO response has been related to the
baseline fibrinogen, baseline transferrin receptor concentra-
tion, and the change in the transferrin receptor concentration
after 2 weeks for EPO therapy.5 The observed increase in
abundance of fragments of both fibrinogen and factor XIII
may be related through thrombin and a result of inflamma-
tion.27 In a study of 100 hemodialysis patients, the authors
concluded that subclinical inflammation was an important
determinant of anemia.28 Furthermore, the authors of
this manuscript were able to look at 51 subjects who had
not received EPO and found that there was a negative
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relationship between hemoglobin and fibrinogen in ESA-treated
subjects but not in non-ESA-treated subjects.
The current study looked at patients who were receiving
EPO for a period of at least 6 months. As such, the results
may be related to the dose of EPO those patients received and
may not represent forward predicting markers. We will need
to study additional patients entering dialysis not receiving
any ESA to validate the utility of these markers. However, in
an analysis not shown, we determined that OSMR better
predicted membership in the two groups than dose, even
though the two groups were defined as a function of dose.
In summary, we performed a peptidomic analysis of the
serum of subjects without overt signs of inflammation or
extraordinary blood loss who were good and poor responders
to exogenous EPO. The analysis resulted in the identification
of 16 peptide fragments that were differentially expressed in
the two groups, with OSMRb and CYHR1 showing the best
association. OSMRb has a demonstrated role in erythropoi-
esis following the production and binding of oncostatin M,
whereas CYHR1 has no known biologic action. The other
identified fragments, fibrinogen a and b, factor XIII,
and compliment C3, were not as strongly associated with
ESA response and may reflect an underlying inflammatory
process. OSMRb and CYHR1 have been identified as
candidate biomarkers of the response to exogenous EPO.
These proteins and their fragments will need to be validated
in larger studies as biomarkers of the response to ESA
therapy.
MATERIALS AND METHODS
Human subjects
The research protocol conformed to the Declaration of Helsinki and
informed consent was obtained from each subject before participa-
tion in the study. The study was approved by the institutional review
boards of both the University of Louisville and the Louisville
Veterans Administration Medical Center. EPO dose and hemoglobin
data were collected over a 5-month period of treatment for 187
hemodialysis patients in the Kidney Disease Program hemodialysis.
We calculated an EPO response index as the EPO dose (per 1000
units) divided by the resulting hemoglobin 1 month later. These
data were averaged over the 5 months of collected data. The mean
data were sorted in ascending order and subjects for the good
response group were selected from the lowest quintile group.
Subjects for the poor response group were selected from the highest
quintile group. EPO resistance was defined as those subjects with the
largest EPO response index values averaged over 5 months.
Subjects were excluded if they changed dialysis modality, had
incomplete data, had not received EPO in 43 of the 5 months
evaluated, had hepatitis C, active lupus or infection, malignancy,
valve disease, and for lack of consent.
Samples and sample handling
Study subjects were asked to donate 20ml of blood for proteomic
analysis following an informed consent process. Blood was collected
in 2–10ml red top vacutainer tubes before the dialysis session,
processed immediately for serum separation, and stored in 0.5ml
aliquots at 80 1C until analyzed.
Peptides were isolated from serum using a Vivaspin 2 (Sartorius
AG, Gottingen, Germany) spin filtration devices housing 5000
Dalton nominal molecular weight cutoff Hydrosart (cellulosic)
membranes. Two peptide fractions, freely soluble and protein
bound, were isolated and assayed using a microBCA method (Pierce,
Rockford, IL). One good responder sample provided insufficient
amounts of protein-bound peptide for study by LC-MALDI-TOF
MS; both the freely soluble and the protein-bound fractions for that
patient were excluded from LC-MALDI-TOF MS studies.
Peptidomic analyses
Isolated peptides were analyzed using a method we previously
published.29 Briefly, LC-MALDI-TOF MS ion chromatograms were
constructed using Data Explorer software (Applied Biosystems, Foster
City, CA) using signal-to-noise criteria of X10 to define a peptide
peak, exported as peak list text files, and used for determination of
differential peptide abundance. Only peptides found in 480%
(n¼ 28) samples were included for further analysis. The integrated
signal areas for the MALDI-TOF MS data for these peptides were
compared using unpaired Student’s t-test. Peptides having P-values
o0.05 (Po0.05) and fold abundance changes of X133 or p75% in
good and poor responders were considered important and used to
create a list of peptides for targeted tandem MS studies.
Computer-assisted tandem MS data analysis
We investigated selected peptides using a tandem MS method we
have previously published.23 The peptide fragmentation information
was searched using Matrix Science Mascot software (version 2.1)
(Matrix Science, Boston, MA) and the Paragon algorithm of Protein
Pilot (Applied Biosystems). Analyses were conducted simultaneously
Table 5 | Statistical analysis of the identified peptides
Peptide m/z Group Gender Interaction ROC
P-valuesa
Increased abundance predicts poor response
OSMR 1273 o0.0001 (o0.0001) 0.040 (1.00) 0.85 (1.00) 0.95
1549 o0.0001 (o0.0001) 0.026 (0.08) 0.21 (0.63) 0.96
1664 o0.0001 (o0.0001) 0.19 (0.56) 0.62 (1.00) 0.99
Sum of
fragments
o0.0001 0.20 0.65 0.98
Increased abundance predicts good response
CYHR1 1488 o0.0001 0.60 0.60 0.91
FGA 1194 0.052 (0.47) 0.49 (1.00) 0.29 (1.00) 0.79
1399 0.081 (0.73) 0.67 (1.00) 0.92 (1.00) 0.62
1463 0.021 (0.19) 0.58 (1.00) 0.33 (1.00) 0.69
1481 0.045 (0.041) 0.46 (1.00) 0.80 (1.00) 0.72
1534 0.063 (0.57) 0.78 (1.00) 0.85 (1.00) 0.62
2466 0.03 (0.27) 0.067 (0.60) 0.85 (1.00) 0.82
2553 0.019 (0.17) 0.27 (1.00) 0.59 (1.00) 0.81
2768 0.053 (0.48) 0.16 (1.00) 0.58 (1.00) 0.77
2931 0.004 (0.036) 0.17 (1.00) 0.33 (1.00) 0.81
Sum of
fragments
0.005 0.17 0.59 0.88
FGB 1552 0.0010 0.89 0.72 0.80
Factor XIII 1210 0.015 0.51 0.71 0.75
CO3 1504 0.07 0.64 0.20 0.74
Abbreviations: CO3, complement C3; CYHR1, cysteine and histidine-rich protein 1;
FGA, fibrinogen a chain; FGB, fibrinogen/fibrinopeptide B; OSMR, oncostatin M
receptor; ROC, receiver operating characteristic.
aValues in parentheses are P-values following Bonferroni correction for multiple
comparisons.
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against a reversed SwissProt database (uniprot.org) and automated
filtering, retaining peptide scoring with q-values (false discovery rate
filter) p0.10. We sought to identify the protein source for the
discriminating serum peptides using tandem mass spectrometry.
Unidentified high-quality spectra at this point were suspected to be
post-translationally modified. To address this problem, the data
were reanalyzed using two bioinformatic approaches. We first used
a post hoc error-tolerant analysis with Mascot software and second,
we employed the Paragon algorithm of Protein Pilot. Both methods
attempt to analyze the data in an iterative approach, considering
known post-translational modifications, polymorphisms, and point
mutations.
Immunoblot analyses for serum protein abundance
We performed immunoblot analyses using a method we have
previously described.30 We determined the serum abundance of
intact OSMRb and CYHR1 using native (denaturing) and Laemmli
(reducing/denaturing) sample buffers. These analyses were con-
ducted using polyclonal antibodies raised to either full-length
human OSMRb (cat. no. ab67805; Abcam, Cambridge, MA) or an
internal epitope of human CYHR1 (sc-87664; Santa Cruz Biotech-
nology, Santa Cruz, CA). The expression of OSMRb and CYHR1
were examined using previously unthawed, contemporaneous
aliquots of the serum sample set used for peptidomic analyses.
Analysis of serum markers of inflammation and iron status
High-sensitivity human serum cytokine measurements were made
under contract services by Millipore (Billerica, MA) labs. High-
sensitivity C-reactive protein measurements in patient serum
samples were made using the Immulite 1000 (Siemens Healthcare
Diagnostics, Deerfield, IL) High-Sensitivity C-reactive protein kit
(Diagnostics Products, Los Angeles, CA) according to the manufac-
turer’s guidelines. Hepcidin-25 peptide measurements were made
using the hepcidin-25 peptide enzyme immunoassay kit S-1337
(Bachem Group, Torrance, CA) and using the hepcidin-25 standard
LEAP1 from Peptides International (Louisville, KY) as a positive
control. The R2 was 0.9967 for LEAP1-positive control peptide from
0 to 50 ng/ml using sigmoid regression, whereas it was 0.9969 for the
hepcidin-25 standard provided in Bachem enzyme immunoassay
kit. The coefficient of variation for a given hepcidin-25 concentra-
tion of 1.56 ng/ml was 3.49% intra-assay and 3.43% inter-assay.
Statistical analysis
Statistical analysis was performed using PASW Statistics 18 (SPSS,
Chicago, IL). Comparisons of proportions, means, and means by
gender were done using Pearson’s w2, t-test, and analysis of variance,
respectively. When multiple fragments of the same parent protein
were analyzed, a Bonferroni correction was applied to address the
problem of multiple comparisons and the data were analyzed as the
sum of all fragment abundances. The ability of the identified
biomarkers to discriminate between groups was analyzed using
receiver operating characteristic curve.
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